Faecal Calprotectin Assay

The Joint Authority HUS requests for offers on Faecal calprotectin assay supplies. The Joint Authority HUS involved with this call for tenders is later referred to collectively as the “Client”. The assay is an aid in differentiating irritable bowel syndrome (IBS) of the small intestine, large bowel or stomach from inflammatory bowel disease (IBD), specifically Crohn´s disease and ulcerative colitis. It is also used to determine disease activity and to monitor the response to treatment of IBD. The procurement includes Faecal calprotectin assay test kits/packages. HUSLAB tested in 2021 approximately 35 000 samples. Estimated increase in number of samples is 10 - 15 % / year. HUS shall order the products and optional products included in this agreement on the basis of it's own needs. HUS is not obligated to order a set amount of products from the Supplier, nor does the Agreement give the Supplier the exclusive right to supply the products under this Agreement to the Client. The consumption given in the call for tenders is preliminary, and does not bind the Client. The Agreement is in force for a fixed period of 2 years, and thereafter until terminated. The Client will select one (1) supplier with which it will enter into an agreement. The object of the procurement and the requirements pertaining to it are described in detail in the call for tenders and its appendices.